Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Detailed price information for Lexaria Bioscience Corp WT (LEXXW-Q) from The Globe and Mail including charting and trades.
Pharmaceutical Technology7d
ACC 25: Oral semaglutide reduces cardiovascular events in T2D patients
Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...
Tharimmune announce preclinical TH023 results
Tharimmune (THAR) announced preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized ...
Tharimmune Inc.: Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, toda ...
The Herald SC14d
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
caprylate (SNAC), which has been used to enhance the absorption of GLP-1 peptides, such as semaglutide. Utilization of SNAC to protect infliximab from enzymatic degradation or permeation ...